Multimodal sensor fusion is increasingly used to improve observability for fault diagnosis and prognostics, enabling Remaining Useful Life estimation in complex mechatronic and robotic systems. Yet, real-world deployments remain vulnerable to sensor faults and data integrity issues—including bias and drift, miscalibration, dropouts, saturation, cross-talk, time desynchronization, and domain shift—which can propagate through fusion pipelines and lead to optimistic validation and poor generalization. These challenges are particularly consequential in safety- and health-adjacent applications such as collaborative robots, wearable/rehabilitation devices, and human-centric mechatronic systems where decisions based on faulty sensing may affect both reliability and user safety. This review synthesizes the state of the art on (i) sensor fault taxonomies and fault models relevant to multimodal fusion, (ii) fault-aware fusion strategies spanning data-, feature-, and decision-level integration, and (iii) how sensor faults and uncertainty impact diagnosis and remaining-life estimators. We will conduct a systematic scoping review of peer-reviewed literature, extracting sensor modalities, fault characterization or injection protocols, fusion architectures, validation settings (simulation, hardware-in-the-loop, bench, and in-field/on-body studies), and reporting completeness. Beyond summarizing methods, we provide practical reporting standards for sensor-fusion-based diagnosis and prognostics, including a minimum disclosure set covering synchronization, fault ground truth, missingness handling, leakage controls, uncertainty calibration, and task-relevant metrics. Reusable checklists and evidence tables are included to support more comparable, reproducible, and deployment-ready research.

The COVID-19 pandemic has significantly accelerated the adoption of telemedicine and digital health technologies, revealing their immense potential in managing cancer patients effectively. This article explores the impact of recent technological developments and widened consumer perspectives on personalised healthcare and patient awareness, particularly in oncology. Smartphones and wearable devices have become integral to daily life, promoting healthy lifestyles and supporting cancer patients through remote monitoring and health management. The widespread use of these devices presents an unprecedented opportunity to transform clinical trials and patient care by offering convenient and accessible means of collecting health data continuously and non-invasively. However, to fully harness their potential, it is crucial to establish standardised methods for measuring patient metrics to ensure data reliability and validity. This article also addresses the challenges of integrating these technologies into clinical practice, such as cost, patient and professional reluctance, and technological oversaturation. It emphasises the need for continuous innovation, the development of robust digital infrastructures, and the importance of fostering a supportive environment to integrate these advancements permanently. Ultimately, the convergence of technological innovation and personalised healthcare promises to enhance patient outcomes, improve quality of life, and revolutionise cancer management in the post-COVID era.

This review synthesises fault detection and diagnosis (FDD) methods for robotic actuation in healthcare, where precise, compliant, and safe physical human–robot interaction (pHRI) is essential. Actuator families—harmonic-drive electric transmissions, series-elastic designs, Cable/Bowden mechanisms, permanent-magnet synchronous motors (PMSM), and force–torque-sensed architectures—are mapped to characteristic fault classes and to sensing, residual-generation, and decision pipelines. Four methodological families are examined: model-based observers/parity relations, parameter-estimation strategies, signal-processing with change detection, and data-driven pipelines. Suitability for pHRI is assessed by attention to latency, robustness to movement artefacts, user comfort, and fail-safe behaviour. Aligned with ISO 14971 and the IEC 60601/80601 series, a validation framework is introduced, with reportable metrics—time-to-detect (TTD), minimal detectable fault amplitude (MDFA), and false-alarm rate (FAR)—at clinically relevant thresholds, accompanied by a concise reporting checklist. Across 127 studies (2016–2025), a pronounced technology-dependent structure emerges in the actuator-by-fault relationship; accuracy (ACC/F1) is commonly reported, whereas MDFA, TTD, and FAR are rarely documented. These findings support actuation-aware observers and decision rules and motivate standardised reporting beyond classifier accuracy to enable clinically meaningful, reproducible evaluation in contact-rich pHRI.

Early risk stratification of COVID-19 severity in oncology patients is critical for improving clinical outcomes and optimizing hospital resource allocation. This study proposes a rule-based clinical decision support system (CDSS) designed for integration into digital triage workflows. In practical terms, the score is intended to be applied at hospital admission or triage, where demographic and comorbidity information is routinely available. The computed score can automatically flag high-risk oncology patients for intensified monitoring or early ICU evaluation, supporting rapid resource allocation while preserving clinician decision-making. Using retrospective clinical data from hospitalized oncological patients with confirmed SARS-CoV-2 infection, we developed a scoring algorithm based on four common comorbidities: age ≥ 70, obesity, diabetes mellitus, and hypertension. Each factor was assigned a weighted contribution to a cumulative score ranging from 0 to 7. Patients were classified into three risk levels (low, moderate, high), correlating with observed rates of ICU admission and mortality. The system is built for low-complexity implementation in electronic health records (EHRs) or web-based triage dashboards and includes a software logic model with pseudocode. Results indicate that the score effectively distinguishes patient risk levels with statistical significance (p < 0.01), and can function as an early triage mechanism. The proposed model does not require laboratory data or imaging, making it particularly suitable for rapid deployment in both hospital and remote settings. This work demonstrates a pragmatic, interpretable, and scalable approach to clinical decision support in pandemic contexts involving vulnerable populations such as cancer patients.